Abstract
Functional alterations in synaptic contacts in specific brain areas are a hallmark of major depressive disorder (MDD). Antidepressant treatments not only readjust the aberrant concentrations of neurotransmitters in the synaptic clefts, but have the capacity to reshape neuronal circuits by affecting synaptogenesis and synaptic stabilization in specific regions of the brain. Nevertheless, the underlying molecular mechanisms are still unclear. Glial cells are active partners of neurons in orchestrating molecular signals that regulate the arrangement of neuronal circuits both in the developing and adult brain. Here, we present evidences indicating that glial cells might be substrates of antidepressant action for restructuring neuronal networks that has become miswired after the onset or progression of MDD. We aim to offer an alternative approach (a “gliocentric” view) to study this complex neuropsychiatric disorder and to identify alternative mechanisms of action for the currently available antidepressant therapies. Such knowledge may help to improve current treatment regimens or identify novel targets for the development of more efficacious antidepressant drugs.
Keywords: Astrocyte, major depressive disorder, microglia, mood disorder, synaptic plasticity.
Current Drug Targets
Title:Talking to the Synapse: How Antidepressants Can Target Glial Cells to Reshape Brain Circuits
Volume: 14 Issue: 11
Author(s): Barbara Di Benedetto, Rainer Rupprecht and Boldizsár Czéh
Affiliation:
Keywords: Astrocyte, major depressive disorder, microglia, mood disorder, synaptic plasticity.
Abstract: Functional alterations in synaptic contacts in specific brain areas are a hallmark of major depressive disorder (MDD). Antidepressant treatments not only readjust the aberrant concentrations of neurotransmitters in the synaptic clefts, but have the capacity to reshape neuronal circuits by affecting synaptogenesis and synaptic stabilization in specific regions of the brain. Nevertheless, the underlying molecular mechanisms are still unclear. Glial cells are active partners of neurons in orchestrating molecular signals that regulate the arrangement of neuronal circuits both in the developing and adult brain. Here, we present evidences indicating that glial cells might be substrates of antidepressant action for restructuring neuronal networks that has become miswired after the onset or progression of MDD. We aim to offer an alternative approach (a “gliocentric” view) to study this complex neuropsychiatric disorder and to identify alternative mechanisms of action for the currently available antidepressant therapies. Such knowledge may help to improve current treatment regimens or identify novel targets for the development of more efficacious antidepressant drugs.
Export Options
About this article
Cite this article as:
Benedetto Di Barbara, Rupprecht Rainer and Czéh Boldizsár, Talking to the Synapse: How Antidepressants Can Target Glial Cells to Reshape Brain Circuits, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/1389450111314110011
DOI https://dx.doi.org/10.2174/1389450111314110011 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Computational Study and Synthesis of a New Class of Anticonvulsants with 6 Hz Psychomotor Seizure Test Activity: 2-(1,3-benzodioxol-5-yloxy)- N'-[substituted]-acetohydrazides
Medicinal Chemistry A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications
Current Drug Metabolism Dynorphin Convertases and their Functions in CNS
Current Pharmaceutical Design Conantokins: Peptide Antagonists of NMDA Receptors
Current Medicinal Chemistry Genes, Blame and Loss of Control: is there a Place in Criminal Law for a ‘Genetic Defense’?
Recent Advances in DNA & Gene Sequences (Discontinued) Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design Random Walks on Biomedical Networks
Current Proteomics Pharmacology of Recombinant Low-Voltage Activated Calcium Channels
Current Drug Targets - CNS & Neurological Disorders Editorial [Hot Topic: PET and SPECT in Drug Evaluation and Drug Design Imaging Inflammatory Processes, Tumors, and the Endocannabinoid System(Executive Editor: Aren van Waarde)]
Current Pharmaceutical Design Feature Extraction, Risky Classifications and Fault Diagnosis on Rolling Bearings of EEG Signals Denoised using Stationary Wavelet Transform of Patient Monitoring and IoT
Current Medical Imaging Current and Future Drug Treatments for Glioblastomas
Current Medicinal Chemistry Status Analysis of Herbal Drug Therapies in Epilepsy: Advancements in the Use of Medicinal Plants with Anti-inflammatory Properties
Combinatorial Chemistry & High Throughput Screening Transcriptional Dys-regulation in Anxiety and Major Depression: 5-HT1A Gene Promoter Architecture as a Therapeutic Opportunity
Current Pharmaceutical Design In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology Homocysteine in Neurological Disease: A Marker or a Cause?
CNS & Neurological Disorders - Drug Targets An Insight Into the Anxiolytic Effects of Lignans (Phyllanthin and Hypophyllanthin) and Tannin (Corilagin) Rich Extracts of <i>Phyllanthus amarus</i> : An <i>In-Silico</i> and <i>In-vivo</i> approaches
Combinatorial Chemistry & High Throughput Screening <i>Cannabis Sativa</i> L. Flower and Bud Extracts Inhibited <i>In vitro</i> Cholinesterases and β-Secretase Enzymes Activities: Possible Mechanisms of Cannabis Use in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design